Meningeal hemangiopericytomas (M-HPC) are challenging tumors with a high rate of recurrence despite surgical resection and external beam radiotherapy (EBRT). To better understand the role of single-fraction stereotactic radiosurgery (SRS) for patients with M-HPC, we reviewed our experience with 22 patients (12 men, 10 women) from 1990 until 2010. Twelve patients (55%) underwent a single SRS procedure, whereas 10 patients (45%) had more than one SRS procedure (range 2-6). In total, 47 SRS procedures were performed to treat 64 tumors. Fourteen patients (64%) had undergone prior EBRT (median dose, 56.0 Gy). Follow-up after the initial SRS (median, 66 months) was censored at the time of death (n = 15) or last clinical evaluation (n = 7). Eleven patients (50 %) died of intracranial tumor progression (n = 10) or treatment-related complications (n = 1). One patient (5%) died of systemic disease progression. Disease-specific survival (DSS) at 1-, 3- and 5-years after SRS was 96, 82, and 61%, respectively. Prior EBRT (HR 9.0, 95% CI 1.1-78.1, p < 0.05) and larger initial tumor volume (HR 1.09, 95% CI 1.02-1.2, p = 0.02) were associated with worse DSS. Local tumor control (LTC) after SRS at 1-, 3-, and 5-years was 89, 68, and 59%, respectively. Improved LTC was noted in patients who had not undergone prior EBRT (HR 6.3, 95% CI 2.1-19.5, p = 0.001). One patient (5%) had symptomatic radiation-relation complications after SRS. Overall, single-fraction SRS was effective in providing LTC for more than half of recurrent or residual M-HPC at 5-years after the procedure. Repeat SRS is often required secondary to either distant or local tumor progression.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-014-1521-3DOI Listing

Publication Analysis

Top Keywords

prior ebrt
12
srs
10
single-fraction stereotactic
8
stereotactic radiosurgery
8
meningeal hemangiopericytomas
8
srs procedure
8
undergone prior
8
tumor progression
8
ebrt 95%
8
local tumor
8

Similar Publications

Article Synopsis
  • The study investigates the impact of recent evidence favoring stereotactic body radiation therapy (SBRT) over conventional external beam radiation therapy (EBRT) for treating metastatic spine disease on insurance approval rates.
  • Before the National Comprehensive Cancer Network (NCCN) included this evidence in their guidelines, 25% of trial-eligible patients faced SBRT insurance denials; after inclusion, that rate dropped to 12.5% among a smaller group.
  • Although the reduction in denials is notable, the small sample size makes it statistically insignificant, underscoring the need for more research and timely updates to clinical guidelines.
View Article and Find Full Text PDF

PSA bounce: understanding temporal fluctuations in prostate cancer after external radiotherapy.

Clin Transl Oncol

December 2024

Department of Medicine, School of Medicine and Haalth Sciences, Universitat Internacional de Catalunya, Josep Trueta s/n, 08195, Sant Cugat del Vallès, Spain.

Purpose: Prostate-specific antigen (PSA) bounce is a transient elevation in PSA levels commonly observed after radiotherapy. This study aims to investigate the characteristics, timing, and clinical implications of PSA bounce (PSA-B) in prostate cancer patients treated with external beam radiotherapy (EBRT), exploring potential causes and its relevance in patient management.

Materials And Methods: Between 2013 and 2019, 629 patients with localized prostate cancer were treated with EBRT.

View Article and Find Full Text PDF

Purpose: To compare Italian use with current international guidelines and to evaluate oncological outcomes and toxicity patterns of adjuvant radiation therapy (RT) for endometrial cancer (EC) in Italian women.

Materials And Methods: To conduct a retrospective multicentre Italian study a large database was set up. Inclusion criteria were: accrual between 2010 and 2020, treatment with surgery, post-operative external beam RT (EBRT) and/or interventional radiotherapy (IRT) associated or not with adjuvant chemotherapy.

View Article and Find Full Text PDF

Purpose: The 44/20 and 20/0 randomized trials evaluated whether different external beam radiation therapy (EBRT) dosing regimens prior to brachytherapy affected biochemical failure (BF). We report long-term outcomes of both trials and evaluate whether biological equivalent dose (BED) was associated with reduced BF in the combined trial cohort.

Methods And Materials: Both trials enrolled patients with clinical T1c to T2b, Gleason scores 7 to 9, and/or a pretreatment prostate-specific antigen (PSA) 10 to 20 ng/mL disease.

View Article and Find Full Text PDF
Article Synopsis
  • Endometrial carcinoma (EC) is a prevalent type of gynecological cancer in India, and this study aimed to evaluate how central histopathological reviews impact patient management and outcomes based on data from 75 patients treated between 2013 and 2022.
  • The analysis revealed substantial changes in histopathological findings for nearly all patients (96.3%), with significant alterations influencing treatment decisions for 19 of those reviewed.
  • Most patients were staged I (64%), with treatments including external beam radiotherapy and brachytherapy, demonstrating the importance of thorough pathology review in improving clinical management and outcomes for EC patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!